Published in Genes Dev on April 15, 2001
Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev (2007) 13.05
The hippo signaling pathway in development and cancer. Dev Cell (2010) 10.54
Mst1 and Mst2 maintain hepatocyte quiescence and suppress hepatocellular carcinoma development through inactivation of the Yap1 oncogene. Cancer Cell (2009) 7.39
Nf2/Merlin controls progenitor homeostasis and tumorigenesis in the liver. Genes Dev (2010) 3.77
The Hippo-YAP pathway: new connections between regulation of organ size and cancer. Curr Opin Cell Biol (2008) 3.63
High-molecular-mass hyaluronan mediates the cancer resistance of the naked mole rat. Nature (2013) 3.32
Loss of the tumor suppressor gene NF2, encoding merlin, constitutively activates integrin-dependent mTORC1 signaling. Mol Cell Biol (2009) 3.25
CD44 is required for two consecutive steps in HGF/c-Met signaling. Genes Dev (2002) 3.07
Epithelial cell polarity, stem cells and cancer. Nat Rev Cancer (2011) 3.06
Contact-dependent inhibition of EGFR signaling by Nf2/Merlin. J Cell Biol (2007) 2.89
CD44 in cancer progression: adhesion, migration and growth regulation. J Mol Histol (2004) 2.71
NF2 deficiency promotes tumorigenesis and metastasis by destabilizing adherens junctions. Genes Dev (2003) 2.55
Regulation of CD44 alternative splicing by SRm160 and its potential role in tumor cell invasion. Mol Cell Biol (2006) 1.99
Merlin/NF-2 mediates contact inhibition of growth by suppressing recruitment of Rac to the plasma membrane. J Cell Biol (2005) 1.86
NF2/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth. Mol Cell Biol (2009) 1.78
The NF2 tumor suppressor, Merlin, regulates epidermal development through the establishment of a junctional polarity complex. Dev Cell (2010) 1.67
Self-masking in an intact ERM-merlin protein: an active role for the central alpha-helical domain. J Mol Biol (2006) 1.66
CD44 attenuates activation of the hippo signaling pathway and is a prime therapeutic target for glioblastoma. Cancer Res (2010) 1.64
The NF2 tumor suppressor gene product, merlin, inhibits cell proliferation and cell cycle progression by repressing cyclin D1 expression. Mol Cell Biol (2005) 1.60
Merlin and the ERM proteins--regulators of receptor distribution and signaling at the cell cortex. Trends Cell Biol (2009) 1.54
Hepatocyte growth factor-induced Ras activation requires ERM proteins linked to both CD44v6 and F-actin. Mol Biol Cell (2006) 1.43
Localization to the cortical cytoskeleton is necessary for Nf2/merlin-dependent epidermal growth factor receptor silencing. Mol Cell Biol (2007) 1.42
Domains controlling cell polarity and proliferation in the Drosophila tumor suppressor Scribble. J Cell Biol (2004) 1.41
Neurofibromatosis 2 (NF2) tumor suppressor merlin inhibits phosphatidylinositol 3-kinase through binding to PIKE-L. Proc Natl Acad Sci U S A (2004) 1.34
Inhibition of macrophage migration inhibitory factor decreases proliferation and cytokine expression in bladder cancer cells. BMC Cancer (2004) 1.30
Nf2/Merlin: a coordinator of receptor signalling and intercellular contact. Br J Cancer (2007) 1.30
Merlin: a tumour suppressor with functions at the cell cortex and in the nucleus. EMBO Rep (2012) 1.30
Rheostatic signaling by CD44 and hyaluronan. Cell Signal (2009) 1.30
Listeria monocytogenes exploits ERM protein functions to efficiently spread from cell to cell. EMBO J (2005) 1.28
Proteolytic cleavage of the CD44 adhesion molecule in multiple human tumors. Am J Pathol (2002) 1.26
The cytoskeletal protein ezrin regulates EC proliferation and angiogenesis via TNF-alpha-induced transcriptional repression of cyclin A. J Clin Invest (2005) 1.26
Hyaluronan and hyaluronidase in genitourinary tumors. Front Biosci (2008) 1.24
The neurofibromatosis 2 tumor suppressor gene product, merlin, regulates human meningioma cell growth by signaling through YAP. Neoplasia (2008) 1.23
Arrest of mammalian fibroblasts in G1 in response to actin inhibition is dependent on retinoblastoma pocket proteins but not on p53. J Cell Biol (2003) 1.22
Merlin, a "magic" linker between extracellular cues and intracellular signaling pathways that regulate cell motility, proliferation, and survival. Curr Protein Pept Sci (2010) 1.21
Signal integration in TGF-β, WNT, and Hippo pathways. F1000Prime Rep (2013) 1.15
A microRNA contribution to aberrant Ras activation in gastric cancer. Am J Transl Res (2011) 1.14
Pak1 and PIX regulate contact inhibition during epithelial wound healing. EMBO J (2003) 1.12
Phosphorylation and activity of the tumor suppressor Merlin and the ERM protein Moesin are coordinately regulated by the Slik kinase. J Cell Biol (2006) 1.07
Interactions between Hyaluronan and Its Receptors (CD44, RHAMM) Regulate the Activities of Inflammation and Cancer. Front Immunol (2015) 1.06
The neurofibromatosis type 2 gene product, merlin, reverses the F-actin cytoskeletal defects in primary human Schwannoma cells. Mol Cell Biol (2002) 1.04
Biochemical characterization and function of complexes formed by hyaluronan and the heavy chains of inter-alpha-inhibitor (HC*HA) purified from extracts of human amniotic membrane. J Biol Chem (2009) 1.04
Molecular mechanisms promoting the pathogenesis of Schwann cell neoplasms. Acta Neuropathol (2011) 1.04
Role of hyaluronan and hyaluronan-binding proteins in lung pathobiology. Am J Physiol Lung Cell Mol Physiol (2011) 1.03
Molecular insights into NF2/Merlin tumor suppressor function. FEBS Lett (2014) 1.03
Merlin-deficient human tumors show loss of contact inhibition and activation of Wnt/β-catenin signaling linked to the PDGFR/Src and Rac/PAK pathways. Neoplasia (2011) 1.02
Inhibition of cell movement and proliferation by cell-cell contact-induced interaction of Necl-5 with nectin-3. J Cell Biol (2005) 1.02
The neurofibromatosis 2 protein, merlin, regulates glial cell growth in an ErbB2- and Src-dependent manner. Mol Cell Biol (2008) 1.01
Merlin isoform 2 in neurofibromatosis type 2-associated polyneuropathy. Nat Neurosci (2013) 1.01
Reprogramming cardiomyocyte mechanosensing by crosstalk between integrins and hyaluronic acid receptors. J Biomech (2011) 1.00
Targeting chronic lymphocytic leukemia cells with a humanized monoclonal antibody specific for CD44. Proc Natl Acad Sci U S A (2013) 1.00
Mouse models of neurofibromatosis 1 and 2. Neoplasia (2002) 0.98
Loss of tumor suppressor Merlin in advanced breast cancer is due to post-translational regulation. J Biol Chem (2011) 0.97
NF2-deficient cells depend on the Rac1-canonical Wnt signaling pathway to promote the loss of contact inhibition of proliferation. Oncogene (2010) 0.97
Alternative RNA splicing and cancer. Wiley Interdiscip Rev RNA (2013) 0.96
Frontier of epilepsy research - mTOR signaling pathway. Exp Mol Med (2011) 0.95
Neural stem cell niches: roles for the hyaluronan-based extracellular matrix. Front Biosci (Schol Ed) (2011) 0.95
Modeling NF2 with human arachnoidal and meningioma cell culture systems: NF2 silencing reflects the benign character of tumor growth. Neurobiol Dis (2007) 0.94
Transportin regulates nuclear import of CD44. J Biol Chem (2010) 0.94
Stable alterations of CD44 isoform expression in prostate cancer cells decrease invasion and growth and alter ligand binding and chemosensitivity. BMC Cancer (2010) 0.94
PCBP-1 regulates alternative splicing of the CD44 gene and inhibits invasion in human hepatoma cell line HepG2 cells. Mol Cancer (2010) 0.94
Point mutation in the NF2 gene of HEI-193 human schwannoma cells results in the expression of a merlin isoform with attenuated growth suppressive activity. Mutat Res (2007) 0.93
Evolution and origin of merlin, the product of the Neurofibromatosis type 2 (NF2) tumor-suppressor gene. BMC Evol Biol (2005) 0.92
Astrocytes in aged nonhuman primate brain gray matter synthesize excess hyaluronan. Neurobiol Aging (2011) 0.92
CD44 interacts with EGFR and promotes head and neck squamous cell carcinoma initiation and progression. Oral Oncol (2012) 0.91
Activation of Ras requires the ERM-dependent link of actin to the plasma membrane. PLoS One (2011) 0.91
c-Met recruits ICAM-1 as a coreceptor to compensate for the loss of CD44 in Cd44 null mice. Mol Biol Cell (2011) 0.91
Nuclear signaling from cadherin adhesion complexes. Curr Top Dev Biol (2015) 0.90
Akt phosphorylation of merlin enhances its binding to phosphatidylinositols and inhibits the tumor-suppressive activities of merlin. Cancer Res (2009) 0.89
The importance of nerve microenvironment for schwannoma development. Acta Neuropathol (2016) 0.89
Fluorescence resonance energy transfer analysis of merlin conformational changes. Mol Cell Biol (2010) 0.89
Merlin is a negative regulator of human melanoma growth. PLoS One (2012) 0.89
Adhesion glycoprotein CD44 functions as an upstream regulator of a network connecting ERK, AKT and Hippo-YAP pathways in cancer progression. Oncotarget (2015) 0.89
A Review: Molecular Aberrations within Hippo Signaling in Bone and Soft-Tissue Sarcomas. Front Oncol (2015) 0.88
Regulation of mixed lineage kinase 3 is required for Neurofibromatosis-2-mediated growth suppression in human cancer. Oncogene (2010) 0.87
The 4.1/ezrin/radixin/moesin domain of the DAL-1/Protein 4.1B tumour suppressor interacts with 14-3-3 proteins. Biochem J (2002) 0.87
BMI-1 suppresses contact inhibition and stabilizes YAP in Ewing sarcoma. Oncogene (2010) 0.87
Unfurling of the band 4.1, ezrin, radixin, moesin (FERM) domain of the merlin tumor suppressor. Protein Sci (2011) 0.87
Rac1 is required for Prkar1a-mediated Nf2 suppression in Schwann cell tumors. Oncogene (2012) 0.86
Aberrant Splicing of Estrogen Receptor, HER2, and CD44 Genes in Breast Cancer. Genet Epigenet (2015) 0.85
Role of Merlin/NF2 inactivation in tumor biology. Oncogene (2015) 0.85
Inhibition of angiogenesis by HC·HA, a complex of hyaluronan and the heavy chain of inter-α-inhibitor, purified from human amniotic membrane. Invest Ophthalmol Vis Sci (2011) 0.85
Intracellular domain fragment of CD44 alters CD44 function in chondrocytes. J Biol Chem (2013) 0.84
Platelet-derived growth factor β-receptor, transforming growth factor β type I receptor, and CD44 protein modulate each other's signaling and stability. J Biol Chem (2014) 0.84
FERM domain phosphoinositide binding targets merlin to the membrane and is essential for its growth-suppressive function. Mol Cell Biol (2011) 0.84
Therapeutic potential of HSP90 inhibition for neurofibromatosis type 2. Clin Cancer Res (2013) 0.84
Neuronal merlin influences ERBB2 receptor expression on Schwann cells through neuregulin 1 type III signalling. Brain (2013) 0.84
ADAM17-mediated CD44 cleavage promotes orasphere formation or stemness and tumorigenesis in HNSCC. Cancer Med (2013) 0.84
Neurofibromatosis type 2 tumor suppressor protein, NF2, induces proteasome-mediated degradation of JC virus T-antigen in human glioblastoma. PLoS One (2013) 0.84
Merlin knockdown in human Schwann cells: clues to vestibular schwannoma tumorigenesis. Otol Neurotol (2010) 0.84
Restoration of contact inhibition in human glioblastoma cell lines after MIF knockdown. BMC Cancer (2009) 0.83
Phosphorylation of merlin regulates its stability and tumor suppressive activity. Cell Adh Migr (2007) 0.83
A neuronal function of the tumor suppressor protein merlin. Acta Neuropathol Commun (2014) 0.83
The NF2 tumor suppressor regulates microtubule-based vesicle trafficking via a novel Rac, MLK and p38(SAPK) pathway. Oncogene (2012) 0.83
The tumor suppressor DAL-1/4.1B and protein methylation cooperate in inducing apoptosis in MCF-7 breast cancer cells. Mol Cancer (2006) 0.83
Hyaluronan inhibits postchemotherapy tumor regrowth in a colon carcinoma xenograft model. Mol Cancer Ther (2010) 0.83
Roles of Proteoglycans and Glycosaminoglycans in Wound Healing and Fibrosis. Int J Cell Biol (2015) 0.82
RNA sequencing of Sleeping Beauty transposon-induced tumors detects transposon-RNA fusions in forward genetic cancer screens. Genome Res (2015) 0.82
Identification and characterization of putative tumor suppressor NGB, a GTP-binding protein that interacts with the neurofibromatosis 2 protein. Mol Cell Biol (2007) 0.82
Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc Natl Acad Sci U S A (1992) 35.45
Integrin signaling. Science (1999) 16.44
Transcriptional activation by tetracyclines in mammalian cells. Science (1995) 13.90
CD44 is the principal cell surface receptor for hyaluronate. Cell (1990) 11.01
Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2. Nature (1993) 6.67
A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell (1993) 6.29
Rho-kinase phosphorylates COOH-terminal threonines of ezrin/radixin/moesin (ERM) proteins and regulates their head-to-tail association. J Cell Biol (1998) 5.15
Disruption of hyaluronan synthase-2 abrogates normal cardiac morphogenesis and hyaluronan-mediated transformation of epithelium to mesenchyme. J Clin Invest (2000) 4.33
ERM family members as molecular linkers between the cell surface glycoprotein CD44 and actin-based cytoskeletons. J Cell Biol (1994) 4.09
Structure of the ERM protein moesin reveals the FERM domain fold masked by an extended actin binding tail domain. Cell (2000) 3.94
Control of growth of mammalian cells in cell culture. Nature (1975) 3.86
A genetic study of type 2 neurofibromatosis in the United Kingdom. I. Prevalence, mutation rate, fitness, and confirmation of maternal transmission effect on severity. J Med Genet (1992) 3.63
Density dependent inhibition of cell growth in culture. Nature (1967) 3.51
Ezrin/radixin/moesin (ERM) proteins bind to a positively charged amino acid cluster in the juxta-membrane cytoplasmic domain of CD44, CD43, and ICAM-2. J Cell Biol (1998) 3.39
Ezrin self-association involves binding of an N-terminal domain to a normally masked C-terminal domain that includes the F-actin binding site. Mol Biol Cell (1995) 3.36
Conditional biallelic Nf2 mutation in the mouse promotes manifestations of human neurofibromatosis type 2. Genes Dev (2000) 2.72
Mice heterozygous for a mutation at the Nf2 tumor suppressor locus develop a range of highly metastatic tumors. Genes Dev (1998) 2.66
Morphogenic effects of ezrin require a phosphorylation-induced transition from oligomers to monomers at the plasma membrane. J Cell Biol (2000) 2.45
CD44 isoforms containing exon V3 are responsible for the presentation of heparin-binding growth factor. J Cell Biol (1995) 2.38
Interaction between CD44 and hyaluronate is directly implicated in the regulation of tumor development. J Exp Med (1994) 2.37
Rho- and rac-dependent assembly of focal adhesion complexes and actin filaments in permeabilized fibroblasts: an essential role for ezrin/radixin/moesin proteins. J Cell Biol (1997) 2.35
Increased tyrosine kinase activity associated with the protein encoded by the activated neu oncogene. Proc Natl Acad Sci U S A (1988) 2.31
CD44H regulates tumor cell migration on hyaluronate-coated substrate. J Cell Biol (1992) 2.28
Inhibition of DNA synthesis in cultures of 3T3 cells by isolated surface membranes. Proc Natl Acad Sci U S A (1977) 2.18
ERM proteins: head-to-tail regulation of actin-plasma membrane interaction. Trends Biochem Sci (1997) 2.12
Ezrin: a protein requiring conformational activation to link microfilaments to the plasma membrane in the assembly of cell surface structures. J Cell Sci (1997) 2.11
Ezrin oligomers are major cytoskeletal components of placental microvilli: a proposal for their involvement in cortical morphogenesis. J Cell Biol (1995) 2.08
Production and characterization of multiple-layered populations of animal cells. J Cell Biol (1965) 2.02
Interaction between the adhesion receptor, CD44, and the oncogene product, p185HER2, promotes human ovarian tumor cell activation. J Biol Chem (1997) 1.86
Ezrin has properties to self-associate at the plasma membrane. J Cell Sci (1994) 1.85
The structure and function of hyaluronan: An overview. Immunol Cell Biol (1996) 1.84
A splice variant of CD44 expressed in the apical ectodermal ridge presents fibroblast growth factors to limb mesenchyme and is required for limb outgrowth. Genes Dev (1998) 1.73
Cell contact-dependent signaling. Dev Biol (1996) 1.70
Heterotypic and homotypic associations between ezrin and moesin, two putative membrane-cytoskeletal linking proteins. Proc Natl Acad Sci U S A (1993) 1.70
Identification and functional analysis of the ezrin-binding site in the hyaluronan receptor, CD44. Curr Biol (1998) 1.61
Density-dependent inhibition of growth involves prevention of EGF receptor activation by E-cadherin-mediated cell-cell adhesion. Exp Cell Res (1996) 1.60
Structural analysis of Drosophila merlin reveals functional domains important for growth control and subcellular localization. J Cell Biol (1998) 1.58
Heparan sulfate-modified CD44 promotes hepatocyte growth factor/scatter factor-induced signal transduction through the receptor tyrosine kinase c-Met. J Biol Chem (1999) 1.58
Interdomain binding mediates tumor growth suppression by the NF2 gene product. Oncogene (1997) 1.55
Regulation of the neurofibromatosis type 2 tumor suppressor protein, merlin, by adhesion and growth arrest stimuli. J Biol Chem (1998) 1.54
Interdomain interactions of radixin in vitro. J Biol Chem (1995) 1.54
Stress-activated protein kinases are negatively regulated by cell density. EMBO J (1998) 1.43
Ruffling membrane, stress fiber, cell spreading and proliferation abnormalities in human Schwannoma cells. Oncogene (1998) 1.38
CD44 enhances neuregulin signaling by Schwann cells. J Cell Biol (2000) 1.38
Central neurofibromatosis with bilateral acoustic neuroma. Adv Neurol (1981) 1.34
Nf1-deficient mouse Schwann cells are angiogenic and invasive and can be induced to hyperproliferate: reversion of some phenotypes by an inhibitor of farnesyl protein transferase. Mol Cell Biol (1997) 1.33
Neurofibromatosis 2 tumor suppressor protein colocalizes with ezrin and CD44 and associates with actin-containing cytoskeleton. J Cell Sci (1997) 1.33
Increased expression of the NF2 tumor suppressor gene product, merlin, impairs cell motility, adhesionand spreading. Hum Mol Genet (1999) 1.27
Defects in neurofibromatosis 2 protein function can arise at multiple levels. Hum Mol Genet (1998) 1.25
Homotypic and heterotypic interaction of the neurofibromatosis 2 tumor suppressor protein merlin and the ERM protein ezrin. J Cell Sci (1999) 1.22
Isolation and characterization of Schwann cells from neurofibromatosis type 2 patients. Neurobiol Dis (1998) 1.12
Hyaluronate-independent metastatic behavior of CD44 variant-expressing pancreatic carcinoma cells. Cancer Res (1996) 1.11
Inhibition of DNA synthesis in SV3T3 cultures by isolated 3T3 plasma membranes. J Cell Biol (1983) 1.09
Interdomain interaction of merlin isoforms and its influence on intermolecular binding to NHE-RF. J Biol Chem (1999) 1.06
Neural cell adhesion molecule mediates contact-dependent inhibition of growth of near-diploid mouse fibroblast cell line m5S/1M. J Cell Biol (1991) 1.06
Isolation and characterization of a 60-70-kD plasma membrane glycoprotein involved in the contact-dependent inhibition of growth. J Cell Biol (1990) 1.00
Merlin differs from moesin in binding to F-actin and in its intra- and intermolecular interactions. Biochem Biophys Res Commun (1998) 0.96
Schwann cell tumors express characteristic patterns of CD44 splice variants. J Neurooncol (1995) 0.89
Establishment of primary vestibular schwannoma cultures from neurofibromatosis type-2 patients. Int J Oncol (1999) 0.86
The nuclear receptor superfamily: the second decade. Cell (1995) 24.99
Phorbol ester-inducible genes contain a common cis element recognized by a TPA-modulated trans-acting factor. Cell (1987) 20.61
A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell (1991) 7.29
Steroid hormone receptors: many actors in search of a plot. Cell (1995) 7.22
Antitumor promotion and antiinflammation: down-modulation of AP-1 (Fos/Jun) activity by glucocorticoid hormone. Cell (1990) 6.56
DNA binding of the glucocorticoid receptor is not essential for survival. Cell (1998) 6.40
Conjugation proteins encoded by the F sex factor. Nature (1977) 5.23
12-O-tetradecanoyl-phorbol-13-acetate induction of the human collagenase gene is mediated by an inducible enhancer element located in the 5'-flanking region. Mol Cell Biol (1987) 4.86
Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients. Nature (1992) 4.42
ATF-2 is preferentially activated by stress-activated protein kinases to mediate c-jun induction in response to genotoxic agents. EMBO J (1995) 4.28
Requirement for fos gene expression in the transcriptional activation of collagenase by other oncogenes and phorbol esters. Cell (1988) 4.13
UV-induced DNA damage is an intermediate step in UV-induced expression of human immunodeficiency virus type 1, collagenase, c-fos, and metallothionein. Mol Cell Biol (1989) 3.83
Subfragments of the large terminal repeat cause glucocorticoid-responsive expression of mouse mammary tumor virus and of an adjacent gene. Proc Natl Acad Sci U S A (1983) 3.42
Comparison of human stromelysin and collagenase by cloning and sequence analysis. Biochem J (1986) 3.31
Export without proteolytic processing of inner and outer membrane proteins encoded by F sex factor tra cistrons in Escherichia coli minicells. Proc Natl Acad Sci U S A (1979) 3.31
Cross-coupling of the NF-kappa B p65 and Fos/Jun transcription factors produces potentiated biological function. EMBO J (1993) 3.28
CD44 variant exon epitopes in primary breast cancer and length of survival. Lancet (1995) 3.07
Participation in normal immune responses of a metastasis-inducing splice variant of CD44. Science (1992) 3.05
Heterodimer formation of cJun and ATF-2 is responsible for induction of c-jun by the 243 amino acid adenovirus E1A protein. EMBO J (1993) 2.83
Soluble CD44 inhibits melanoma tumor growth by blocking cell surface CD44 binding to hyaluronic acid. Oncogene (2001) 2.67
Posttranscriptional regulation of c-fos mRNA expression. Nucleic Acids Res (1987) 2.66
Induction of metallothionein and other mRNA species by carcinogens and tumor promoters in primary human skin fibroblasts. Mol Cell Biol (1986) 2.63
A distinct modulating domain in glucocorticoid receptor monomers in the repression of activity of the transcription factor AP-1. EMBO J (1994) 2.58
Long terminal repeats of endogenous mouse mammary tumour virus contain a long open reading frame which extends into adjacent sequences. Nature (1982) 2.48
Hormonal response region in the mouse mammary tumor virus long terminal repeat can be dissociated from the proviral promoter and has enhancer properties. Proc Natl Acad Sci U S A (1985) 2.47
Activation of the c-fos gene by UV and phorbol ester: different signal transduction pathways converge to the same enhancer element. Oncogene (1988) 2.43
Expression of CD44 variant proteins in human colorectal cancer is related to tumor progression. Cancer Res (1993) 2.39
Autoregulation of fos: the dyad symmetry element as the major target of repression. EMBO J (1989) 2.37
CD44 splice variants confer metastatic behavior in rats: homologous sequences are expressed in human tumor cell lines. Cancer Res (1991) 2.36
Repression of inflammatory responses in the absence of DNA binding by the glucocorticoid receptor. EMBO J (2001) 2.34
Optic pathway gliomas in children with neurofibromatosis 1: consensus statement from the NF1 Optic Pathway Glioma Task Force. Ann Neurol (1997) 2.28
Involvement of growth factor receptors in the mammalian UVC response. Cell (1994) 2.28
Astrocyte-specific expression of activated p21-ras results in malignant astrocytoma formation in a transgenic mouse model of human gliomas. Cancer Res (2001) 2.13
(6-4)Photoproducts are removed from the DNA of UV-irradiated mammalian cells more efficiently than cyclobutane pyrimidine dimers. Mutat Res (1985) 2.07
A human homologue of the rat metastasis-associated variant of CD44 is expressed in colorectal carcinomas and adenomatous polyps. J Cell Biol (1993) 2.06
cDNA cloning of the type 1 neurofibromatosis gene: complete sequence of the NF1 gene product. Genomics (1991) 2.03
Prevention of tumor metastasis formation by anti-variant CD44. J Exp Med (1993) 2.03
Alterations of BRAF and HIPK2 loci predominate in sporadic pilocytic astrocytoma. Neurology (2009) 2.00
A novel function of the transforming domain of E1a: repression of AP-1 activity. Cell (1990) 1.97
DNA damage induced p53 stabilization: no indication for an involvement of p53 phosphorylation. Oncogene (1999) 1.96
Dephosphorylation of receptor tyrosine kinases as target of regulation by radiation, oxidants or alkylating agents. EMBO J (1996) 1.96
Coupling of signal transduction to alternative pre-mRNA splicing by a composite splice regulator. EMBO J (1998) 1.93
DNA sequences outside the receptor-binding sites differently modulate the responsiveness of the mouse mammary tumour virus promoter to various steroid hormones. EMBO J (1988) 1.93
Regulation of synthesis of a major outer membrane protein: cyclic AMP represses Escherichia coli protein III synthesis. Proc Natl Acad Sci U S A (1979) 1.93
Plexiform neurofibromas in NF1: toward biologic-based therapy. Neurology (2002) 1.90
UV-induced activation of AP-1 involves obligatory extranuclear steps including Raf-1 kinase. EMBO J (1993) 1.86
High-resolution, dual-platform aCGH analysis reveals frequent HIPK2 amplification and increased expression in pilocytic astrocytomas. Oncogene (2008) 1.84
Regulation of alternative pre-mRNA splicing by the ERK MAP-kinase pathway. EMBO J (2001) 1.83
CD44 variants but not CD44s cooperate with beta1-containing integrins to permit cells to bind to osteopontin independently of arginine-glycine-aspartic acid, thereby stimulating cell motility and chemotaxis. Cancer Res (1999) 1.82
UV-induced extracellular factor from human fibroblasts communicates the UV response to nonirradiated cells. Cell (1984) 1.80
Hyaluronate receptors: key players in growth, differentiation, migration and tumor progression. Curr Opin Cell Biol (1994) 1.79
The Fos and Jun/AP-1 proteins are involved in the downregulation of Fos transcription. Oncogene (1989) 1.78
CREB is activated by UVC through a p38/HOG-1-dependent protein kinase. EMBO J (1997) 1.78
Activated human lymphocytes and aggressive non-Hodgkin's lymphomas express a homologue of the rat metastasis-associated variant of CD44. J Exp Med (1993) 1.77
In vivo and in vitro phosphorylation of DNA-dependent RNA polymerase of Escherichia coli by bacteriophage-T7-induced protein kinase. Proc Natl Acad Sci U S A (1975) 1.76
Malignant peripheral nerve sheath tumors in neurofibromatosis 1. Am J Med Genet (2000) 1.76
I kappaB alpha-independent downregulation of NF-kappaB activity by glucocorticoid receptor. EMBO J (1997) 1.73
A splice variant of CD44 expressed in the apical ectodermal ridge presents fibroblast growth factors to limb mesenchyme and is required for limb outgrowth. Genes Dev (1998) 1.73
Interference between pathway-specific transcription factors: glucocorticoids antagonize phorbol ester-induced AP-1 activity without altering AP-1 site occupation in vivo. EMBO J (1992) 1.72
Transcriptional cross-talk, the second mode of steroid hormone receptor action. J Mol Med (Berl) (1998) 1.69
Differential expression of CD44 splice variants in intestinal- and diffuse-type human gastric carcinomas and normal gastric mucosa. Cancer Res (1993) 1.68
Splicing choice from ten variant exons establishes CD44 variability. Nucleic Acids Res (1993) 1.68
Differential effects of the adenovirus E1A oncogene on members of the AP-1 transcription factor family. Mol Cell Biol (1990) 1.66
Sequential DNA damage-independent and -dependent activation of NF-kappaB by UV. EMBO J (1998) 1.55
Interdomain binding mediates tumor growth suppression by the NF2 gene product. Oncogene (1997) 1.55
Cancer-related gene expression profiles in NF1-associated pilocytic astrocytomas. Neurology (2001) 1.54
Protein kinase induction in Escherichia coli by bacteriophage T7. Proc Natl Acad Sci U S A (1974) 1.54
DNA damage-induced gene expression: signal transduction and relation to growth factor signaling. Rev Physiol Biochem Pharmacol (1992) 1.52
CD44 acts both as a growth- and invasiveness-promoting molecule and as a tumor-suppressing cofactor. Ann N Y Acad Sci (2000) 1.52
CD44 splice variants: metastases meet lymphocytes. Immunol Today (1993) 1.50
Ligand-independent activation of platelet-derived growth factor receptor is a necessary intermediate in lysophosphatidic, acid-stimulated mitogenic activity in L cells. Proc Natl Acad Sci U S A (1998) 1.47
An essential role for CD44 variant isoforms in epidermal Langerhans cell and blood dendritic cell function. J Cell Biol (1997) 1.46
Mutations in the neurofibromatosis 1 gene in sporadic malignant melanoma cell lines. Nat Genet (1993) 1.45